CAPS - calcyphosine Gene
Also Known as CAPS1
Species: Homo sapiens
About CAPS
This gene has 5 transcripts (splice variants), 98 orthologues and 5 paralogues. Broad expression in lung (RPKM 22.4), endometrium (RPKM 13.8) and 21 other tissues.
Summary
This gene encodes a calcium-binding protein, which may play a role in the regulation of ion transport. A similar protein was first described as a potentially important regulatory protein in the dog thyroid and was termed as R2D5 antigen in rabbit. Alternative splicing of this gene generates two transcript variants. [provided by RefSeq, Jul 2008]
CAPS Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_004058.5 | NP_004049.3 | calcyphosin isoform a |
| NM_080590.4 | NP_542157.3 | calcyphosin isoform b |
CAPS Protein Structure
EF-hand_7: EF-hand domain pair (26 - 85)
EF-hand_7: EF-hand domain pair (100 - 166)
- 0
- 100
- 189 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
calcyphosin |
|
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Clonorchiasis |
|
|
| Diseases | Alias | |
|---|---|---|
| Waldenstroem'S Macroglobulinemia |
Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-109025 | Baloxavir marboxil | Inhibitor | 99.96% | Unkown |
| HY-109025A | Baloxavir | Inhibitor | 99.92% | Unkown |
| HY-A0148A | Halofantrine hydrochloride | Inhibitor | 99.90% | Yes |
| HY-17452A | Cefditoren Pivoxil | Inhibitor | 99.29% | Unkown |
| HY-109025R | Baloxavir marboxil (Standard) | Inhibitor | 99.90% | Unkown |
| HY-14956 | Nemonoxacin | Inhibitor | 99.77% | Unkown |
| HY-17452 | Cefditoren sodium | Inhibitor | 99.70% | Unkown |
| HY-116229 | Gemifloxacin | Inhibitor | / | Unkown |
| HY-A0148 | Halofantrine | Inhibitor | / | Unkown |
| HY-17452AR | Cefditoren Pivoxil (Standard) | Inhibitor | / | Unkown |
| HY-A0148AR | Halofantrine hydrochloride (Standard) | Inhibitor | / | Unkown |
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-145586A | Onradivir monohydrate | Inhibitor | / | Phase 3 |
| HY-143744 | Suraxavir marboxil | Inhibitor | / | Phase 3 |
| HY-139553 | Zunsemetinib | Inhibitor | 99.99% | Phase 2 |
| HY-105172 | TT-232 | Agonist | 98.72% | Phase 2 |
| HY-12914 | V116517 | Antagonist | / | Phase 2 |
Pre-clinical Phase
Orthologs Information
| Species | Symbol | Source | ID |
|---|---|---|---|
| Rattus norvegicus | CAPS | RGD | RGD:41237504 |
| Canis familiaris | CAPS | VGNC | VGNC:54265 |
| Macaca mulatta | CAPS | VGNC | VGNC:108145 |
| Bos taurus | CAPS | VGNC | VGNC:26753 |
| Others | CAPS | NCBI |